The Impact of Mineralocorticoid Receptor Antagonists in HF Patients Across the EF Range
25 Oct, 24
Introduction
Studies have demonstrated the benefits of steroidal mineralocorticoid receptor antagonists (MRAs, eplerenone and spironolactone) in reducing the hospitalizations and death in patients with heart failure and reduced ejection fraction (HFrEF). Consequently, MRAs are recommended in patients with HFrEF. Nevertheless, the benefits of MRAs in patients with heart failure and mildly reduced ejection fraction (HFmrEF) or heart failure and preserved ejection fraction (HFpEF) remain unclear.
Aim
To ascertain the impact of MRAs in four trials that enrolled patients with heart failure across the range of ejection fractions.
Patient Profile
- Patients with HFrEF, HFmrEF or HFpEF who participated in one of the following trials:
- The RALES trial (spironolactone): Patients with HF and left ventricular ejection fraction (LVEF) ≤35%.
- The EMPHASIS-HF trial (eplerenone): Patients with HF and LVEF of ≤35% (if LVEF >30% to 35%, a QRS duration of >130 msec on electrocardiography was required).
- The TOPCAT trial (spironolactone): Patients with HF and LVEF of ≥45%.
- The FINEARTS-HF trial (finerenone): Patients with HF and LVEF of ≥40%.
Methods
Study Design
- A prespecified, individual patient level meta-analysis of the RALES, EMPHASIS-HF, TOPCAT and FINEARTS-HF trials.
Outcomes
Primary Outcome
- A composite of time to first hospitalization for HF or cardiovascular (CV) death.
Secondary Outcomes
- Time to first hospitalization for HF, total HF hospitalizations and CV death, CV death, and all-cause mortality.
Safety Outcomes
- Changes in serum potassium, and systolic blood pressure (SBP).
Results
- A total of 13846 patients were included in this meta-analysis.
- Treatment with MRAs reported a 23% significant reduction in the risk of CV death or HF hospitalization [hazard ratio (HR): 0·77; 95% confidence interval (CI): 0·72–0·83].
- A statistically significant interaction by trials and treatment was evident (p for interaction=0·0012) due to the greater efficacy in HFrEF trials (HR: 0·66; 95% CI: 0·59–0·73) with HFmrEF or HFpEF trials (HR: 0·87; 95% CI: 0·79–0·95).
- There were significant reductions in HF hospitalization in the HFrEF trials (HR: 0·63; 95% CI: 0·55–0·72) and the HFmrEF or HFpEF trials (HR: 0·82; 95% CI: 0·74–0·91). A similar pattern was observed for total HF hospitalizations with or without CV death.
- A reduction in CV death was observed in the HFrEF trials (HR: 0·72; 95% CI: 0·63–0·82) but not in the HFmrEF or HFpEF trials (HR: 0·92; 95% CI: 0·80–1·05).
- A reduction in all-cause death was observed in the HFrEF trials (HR: 0·73; 95% CI: 0·65–0·83) but not in the HFmrEF or HFpEF trials (HR: 0·94; 95% CI: 0·85–1·03).
- The risk of hyperkalemia was doubled with an MRA, compared with placebo [odds ratio (OR): 2·27; 95% CI: 2·02–2·56), though the incidence of serious hyperkalemia (serum potassium >6·0 mmol/L) was low (2·9% vs 1·4%); the risk of hypokalemia (potassium <3·5 mmol/L) was reduced to half (OR: 0·51; 95% CI: 0·45–0·57; 7% vs 14%).
- The incidence of hypotension was more common in the HFrEF trials, but there was no statistically significant heterogeneity for the effect of treatment on SBP <90 mm Hg by trial group (7% vs 5% in the HFrEF trials and 5% vs 3% in the HFmrEF or HFpEF trials).
Conclusions
- The meta-analysis demonstrated that steroidal MRAs reduced the risk of CV death or HF hospitalization in patients with HFrEF. The non-steroidal MRAs reduced this risk of CV death or HF hospitalization in patients with HFmrEF or HFpEF.
- Benefits of MRAs remained consistent across the patient subgroups.
- Clinicians should consider treatment with an MRA for all patients with HF who do not have a contraindication to this treatment.
Lancet 2024; 404: 1119–31
Related Topics









